McKesson Earnings Call Highlights Specialty and Tech Strength

McKesson Corporation ((MCK)) has held its Q3 earnings call. Read on for the main highlights of the call.

McKesson Posts Robust Quarter as Growth Engines Fire on All Cylinders

McKesson’s latest earnings call painted a decidedly upbeat picture, with management leaning into broad-based strength across the portfolio, double‑digit earnings growth, and another guidance raise. Executives acknowledged some pockets of near-term pressure—particularly in medical-surgical and around technology spending and GLP‑1 channel dynamics—but repeatedly emphasized that underlying demand, margin expansion, cash generation, and strategic execution are all trending ahead of plan.

Record Revenue and EPS Underscore Operating Momentum

McKesson delivered another record quarter, with consolidated revenue climbing 11% year over year to $106.2 billion. Diluted EPS advanced even faster, up 16% to $9.34, powered by solid operational performance and contributions from recent acquisitions. The combination of strong top-line growth and expanding earnings underlines the company’s ability to scale its distribution and services platforms while improving profitability—a key point for investors focused on sustainable earnings power rather than one‑off gains.

Guidance Raised Again as Growth Outlook Strengthens

Reflecting its confidence in the trajectory of the business, McKesson raised its full-year adjusted EPS guidance to a range of $38.80 to $39.20, implying 17% to 19% year-over-year growth. Looking further ahead to fiscal 2026, management outlined expectations for revenue growth of 12% to 16% and operating profit growth of 13% to 17%. The upgraded outlook signals not only durable demand in core drug distribution, oncology, and tech solutions, but also management’s belief that recent investments and acquisitions will continue to pay off in the coming years.

Oncology & Multispecialty Surges, Buoyed by Acquisitions

The Oncology & Multispecialty segment was a standout, with revenue jumping 37% to $13.0 billion and operating profit soaring 57% to $366 million. Acquisitions such as Prism and Core Ventures were a meaningful driver, contributing roughly 13% to third-quarter segment revenue growth and expected to deliver about 30% to 34% of this segment’s operating profit growth in fiscal 2026. This rapid growth reinforces McKesson’s strategy of deepening its presence in high‑value specialty markets, where clinical complexity and service intensity support stronger margins and tighter customer relationships.

North American Pharmaceutical Distribution Maintains Solid Growth

North American Pharmaceutical, the company’s largest segment, continued to post healthy gains. Revenues rose 9% to $88.3 billion, driven by higher prescription volumes, strong performance in specialty distribution, and improving volumes across health systems. Segment operating profit increased 6% to $872 million, reflecting both steady demand and the ability to manage costs in a competitive distribution landscape. While growth here is less explosive than in oncology, the consistency of this engine remains central to McKesson’s overall earnings profile.

GLP‑1 Distribution Becomes a Major Revenue Driver

GLP‑1 therapies, used for diabetes and weight management, remained a powerful growth catalyst. McKesson generated $14.0 billion in GLP‑1 distribution revenue during the quarter, up $3.0 billion, or 26% year over year, and 7% sequentially. This surge reflects strong demand trends across these therapies, positioning McKesson as a key player in one of the fastest-growing categories in healthcare. While management signaled some uncertainty around future channel dynamics, current demand levels are clearly adding meaningful scale to the top line.

Prescription Technology Solutions Delivers Double-Digit Profit Growth

McKesson’s Prescription Technology Solutions (RxTS) business continued to prove its strategic value, with revenue up 9% to $1.5 billion and operating profit increasing 18% to $277 million. Growth was driven by rising demand for services that improve drug access and affordability, including prior authorization support. The company added 50 new programs across 43 brands, underscoring its ability to win new pharmaceutical partners and expand its role in navigating patient access barriers. This higher-margin digital and services business is becoming an increasingly important contributor to overall profitability.

Profitability and Cash Generation Support Shareholder Returns

McKesson’s profitability metrics and cash generation remained strong. Gross profit rose 10% to $3.7 billion, while operating profit increased 13% to $1.7 billion. Operating expenses improved by 138 basis points as a percentage of gross profit, highlighting ongoing efficiency gains. Free cash flow in the quarter reached $1.1 billion, and the trailing 12‑month figure stood at a sizable $9.6 billion. The company ended the period with $3.0 billion in cash and returned $781 million to shareholders, including $680 million in share repurchases, underscoring its capacity to fund growth while consistently returning capital.

Balance Sheet Strength Underpins Aggressive Capital Returns

The company highlighted a strong balance sheet and a disciplined capital return strategy. Management plans about $2.0 billion in share repurchases for fiscal 2026 and expects free cash flow of $4.4 billion to $4.8 billion. Return on invested capital has improved by roughly 1,900 basis points since fiscal 2020, now exceeding 30%, a striking improvement that signals disciplined investment and efficient capital deployment. McKesson continues to operate with an investment‑grade profile, giving it flexibility to pursue further acquisitions, technology initiatives, and shareholder returns without stretching its balance sheet.

Portfolio Simplification and Medical-Surgical Separation Advance

Strategic portfolio actions also moved forward. McKesson completed the divestiture of its Norway operations, marking its final exit from Europe. It has also achieved key transition service agreements tied to the separation of its medical-surgical business and remains on track toward a potential IPO of that business by the second half of calendar 2027, subject to market and regulatory conditions. These actions are designed to sharpen the company’s focus on higher‑growth, higher‑margin areas, while ultimately unlocking value from the more cyclical medical-surgical unit.

Technology and Automation Drive Productivity Gains

Technology and automation initiatives are starting to show concrete operational benefits. AI‑enabled tools helped each full‑time equivalent support roughly 120 more patients during the annual verification season, showcasing material productivity gains. In supply chain compliance, an AI chat tool for DSCSA inquiries prevented about 75% of questions from escalating, reducing manual workload. In Canada, contact-center automation pilots are approaching nearly 100% service accuracy. Together, these initiatives illustrate how McKesson is investing in digital capabilities to scale its operations more efficiently while improving service quality.

Medical-Surgical Segment Faces Volume and Mix Headwinds

Not all segments participated equally in the upswing. The medical-surgical business reported revenue of $3.0 billion, up just 1% year over year, while operating profit fell 10% to $265 million. Management cited lower physician office volumes and a milder illness season as key factors pressuring profitability. These results highlight the segment’s sensitivity to patient traffic and seasonal illness trends—one reason McKesson is pursuing a separation strategy to reduce the drag of this cyclical business on its overall growth and margin profile.

Quarterly Volatility and Program Dynamics Introduce Execution Risk

Management flagged that certain parts of the business—particularly RxTS and GLP‑1 distribution—can experience notable quarter‑to‑quarter variability. Utilization trends, the timing of product launches, lifecycle changes in pharmaceutical programs, seasonal illness patterns, and supply chain dynamics can all cause short-term swings in performance. While the long‑term trajectory remains positive, this variability introduces some execution risk at the quarterly level and could also influence outcomes into fiscal 2027, a point investors may watch closely when assessing earnings consistency.

GLP‑1 Channel Evolution Remains a Key Wild Card

Despite strong current growth in GLP‑1 distribution, management underscored uncertainty around how new oral GLP‑1 launches and potential shifts toward cash‑pay channels will play out. The key question is how much of future demand will come from net new patients versus share shifts within the category, which could impact utilization patterns and prior authorization volumes. These evolving dynamics make it harder to predict medium‑term trends, even as the category remains a powerful growth engine today.

Tech Spending Rises as Infrastructure Investments Accelerate

McKesson is leaning into technology investments that bring near-term costs but are expected to support long-term efficiency. Corporate expenses rose year over year, and the company plans technology infrastructure spending of $620 million to $650 million for the year. Management also highlighted an incremental technology investment in the fourth quarter, expected to add about $0.05 per share of cost versus the prior year. While these expenditures weigh on near‑term earnings, they are positioned as foundational investments underpinning future automation, analytics, and service capabilities.

Wide Guidance Ranges Highlight Forecast Uncertainty

Some guidance ranges—particularly for North American Pharmaceutical revenue and operating profit—remain relatively wide, reflecting moving pieces in the outlook. Management pointed to variability in below‑the‑line items, including interest expense, guided to $215 million to $235 million, and income attributable to noncontrolling interest, projected at $230 million to $250 million. These elements contribute to some dispersion in overall forecasts and underscore that, despite strong momentum, there are still macro, rate, and mix factors that can influence reported results.

Forward Guidance Signals Confident Multi-Year Growth Path

Looking ahead, McKesson’s updated guidance paints a confident multi‑year growth narrative. For fiscal 2026, management now expects adjusted EPS of $38.80 to $39.20, up 17% to 19% year over year, backed by revenue growth of 12% to 16% and operating profit expansion of 13% to 17%. Segment-wise, North American Pharmaceutical is projected to deliver revenue growth of 10% to 14% and operating profit growth of 8% to 12%. Oncology & Multispecialty is expected to be the primary growth engine, with revenue up 29% to 33% and operating profit up a striking 51% to 55%, helped significantly by Prism Vision and Core Ventures. RxTS is forecast to grow revenue 9% to 13% and operating profit 14% to 18%. On the financial side, McKesson anticipates free cash flow of about $4.4 billion to $4.8 billion, roughly $2 billion of share repurchases, and a weighted average diluted share count around 124 million, with an effective tax rate near 19%. Management acknowledged that incremental technology investments will modestly pressure fourth-quarter EPS, but framed them as necessary to sustain the growth outlook.

In sum, McKesson’s earnings call highlighted a company firing on multiple cylinders: strong revenue and EPS growth, powerful contributions from oncology and specialty, rising high-margin tech solutions, and robust cash generation fueling buybacks. While medical-surgical remains a soft spot and GLP‑1 channel dynamics and technology spending introduce some uncertainty, the overarching message was one of confidence in the company’s strategy and its ability to compound earnings over the coming years—an appealing story for investors seeking exposure to scaled healthcare distribution with growing technology and specialty upside.